Report
Hansa Biopharma AB
Scheelevagen 22,
P.O. Box 785
Phone: +46 46165670p:+46 46165670 LUND, 220 07  Sweden Ticker: HNSAHNSA


Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update


Lund, SwedenApril 14, 2021Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2021 at 8:00 CET on April 22, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Webcast," and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 8 50 55 83 75

United Kingdom: +44 333 300 90 35

United States: +1 833 526 83 82

The webcast will be available on https://streams.eventcdn.net/hansa/2021q1/

Updated Calendar and Events 2021

April 22, 2021               Interim report for Jan-Mar 2021

April 28, 2021               Redeye Orphan Drugs Event, Stockholm (virtual)

May 5, 2021                  Kempen Life Sciences Conference, Amsterdam (virtual)

May 7+14, 2021            Truist US Roadshow (virtual)

May 11, 2021                Nordnet/Proinvestor Biotech event, Copenhagen (virtual)

May 12, 2021                Annual General Meeting 2021

May 19, 2021                RBC Global Healthcare Conference, NYC (virtual)

May 25, 2021                ABG Life Science Seminar, Stockholm (virtual)

June 1, 2021                 Jefferies Healthcare Conference, London (virtual)

June 16, 2021               Citi's 2021 European Healthcare Conference  (virtual)

July 15, 2021                Interim report for Jan-Jun 2021

Aug 25, 2021                Handelsbanken Life Science Innovation Seminar, Stockholm

Sep 1, 2021                  Pareto Healthcare Conference, Stockholm (virtual)

Oct 21, 2021                 Interim report for Jan-Sep 2021

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-host-conference-call-to-provide-interim-results-from-q1-2021-and-business-update,c3324033

https://mb.cision.com/Main/1219/3324033/1400409.pdf


Related Businesses
- - Customer

Copyright © 2024 by CreditRiskMonitor.com (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by CreditRiskMonitor.com, Inc. Except as expressly permitted by CreditRiskMonitor.com, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that CreditRiskMonitor.com, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of CreditRiskMonitor.com, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by CreditRiskMonitor.com, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of CreditRiskMonitor.com, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable.  CreditRiskMonitor.com, Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Tuesday, April 23, 2024